RxDoctor Payments Data

James Kim, MD

Interventional Pain Medicine · Covina, CANPI 1649698481

Payments from drug & device makers

$5,940in general payments, 2019–2025

Across 215 payments — averaging $27.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Medtronic$1K
  • Nalu Medical, Inc.$1K
  • Boston Scientific$1K
  • Stimwave Technologies Incorporated$124
  • Stryker$120
  • plus $617 from 15 others

What the payments were for

  • Food & beverage$5,940100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,940 in reported general payments places this provider in the 65th percentile of 188 interventional pain medicine providers in California.

See all interventional pain medicine providers in California

Medicare billing

Part B allowed, 2024
$74,938
Medicare patients
196
Services billed
1,349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZtlidoLidocaine16$8,186
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen195$5,277
Lidocaine35$3,904
Celecoxib108$2,970
Diclofenac Sodium95$2,685
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen56$1,601
Gabapentin116$1,396
Tizanidine Hcl54$509
Pregabalin28$494
Ibuprofen19$339
Baclofen33$301
Methocarbamol31$271
Duloxetine Hcl19$256
Acetaminophen-CodeineAcetaminophen With Codeine19$251
Tramadol Hcl55$204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Scilex Pharmaceuticals Inc.Ztlido$48$8,18616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 188 interventional pain medicine providers in California.

Other interventional pain medicine in Covina

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →